Reduction of IgE Antibody in Human Allergic Subjects
Status: | Completed |
---|---|
Conditions: | Allergy |
Therapuetic Areas: | Otolaryngology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 8/23/2018 |
Start Date: | January 2011 |
End Date: | June 20, 2017 |
The purpose of this study is to determine whether a neuropeptide, substance P, when injected
along with an allergen, such as ragweed, can reduce allergic reactivity.
along with an allergen, such as ragweed, can reduce allergic reactivity.
Allergic Rhinitis (Hay fever) affects many children and adults and is a risk factor for
development of asthma. This study utilizes the neurotransmitter, substance P, a small
molecule which is present in nerve endings, the brain, skin, lungs and the gastrointestinal
tract. Subjects will receive substance P and a low dosage of an allergen, such as ragweed in
an attempt to reduce allergic reactivity.
development of asthma. This study utilizes the neurotransmitter, substance P, a small
molecule which is present in nerve endings, the brain, skin, lungs and the gastrointestinal
tract. Subjects will receive substance P and a low dosage of an allergen, such as ragweed in
an attempt to reduce allergic reactivity.
Inclusion Criteria:
- positive immediate type skin test to ragweed or grass pollen or a third (standardized)
allergen if both ragweed and grass pollen allergen are not positive
- volunteers should be available for allergen injections and then cutaneous titrations
for approximately 1 year from the start of the enrollment period
Exclusion Criteria:
- volunteer is pregnant or lactating
- abnormal electrocardiogram for subjects over 50 years of age
- use of beta adrenergic antagonists or tricyclic antidepressants
We found this trial at
1
site
303 E Chicago Ave
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
Click here to add this to my saved trials